News Releases

Date	Title and Summary	View
June 23, 2022	KalVista Pharmaceuticals to Present Data at the 2022 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 23, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of...	Additional Formats PDF Version
June 8, 2022	KalVista Pharmaceuticals Presents Promising Preclinical Data for Oral Factor XIIa Inhibitor Program – First preclinical data presented for structurally diverse oral Factor XIIa inhibitors - – Additional Sebetralstat data also presented - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 8, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company...	Additional Formats PDF Version
June 3, 2022	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 3, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 20,000 shares of...	Additional Formats PDF Version
June 1, 2022	KalVista Pharmaceuticals to Present at 13th Annual Jefferies Healthcare Conference CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 1, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be...	Additional Formats PDF Version
May 27, 2022	KalVista Pharmaceuticals Announces Changes to Board of Directors – Patrick A. Treanor Appointed Effective Immediately – – Dan Soland Resigns in Planned Transition – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 27, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development,...	Additional Formats PDF Version
May 17, 2022	KalVista Pharmaceuticals Announces Non-Proprietary Name Selection for KVD900 – “Sebetralstat” Approved by WHO and USAN – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 17, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease...	Additional Formats PDF Version
April 11, 2022	KalVista Pharmaceuticals to Present at 21st Annual Needham Virtual Healthcare Conference CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 11, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be...	Additional Formats PDF Version
April 4, 2022	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 4, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of...	Additional Formats PDF Version
March 22, 2022	KalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental Allergy CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 22, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the publication...	Additional Formats PDF Version
March 10, 2022	KalVista Pharmaceuticals Reports Third Fiscal Quarter Results – KVD900 Phase 3 KONFIDENT Trial Initiated – – KVD824 Phase 2 KOMPLETE Clinical Trial Enrollment on Track – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 10, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery,...	Additional Formats PDF Version